Franklin Genomic Advancements Fund A (Ydis) EUR
UMushroom community rating:
0.00
0 votes
No rating yet
NegativeNeutralPositive
General Objective
The Franklin Genomic Advancements Fund aims to increase the value of its investments over the medium to long term. Classified as Article 8 under EU Sustainable Finance Disclosure Regulation, the Fund pursues an actively managed investment strategy and primarily invests in equity securities issued by companies within health care related industries worldwide.
Fund Exposure
The Fund is characterized by its exposure to equity securities issued by companies of any size operating within health care related industries globally, including in emerging markets. The sector breakdown includes significant allocations to biotechnology, life sciences tools & services, pharmaceuticals, and other health care sectors.
Risks
Investing in the Franklin Genomic Advancements Fund carries risks such as concentration risk, where the Fund invests in relatively few holdings or sectors, leading to potentially more volatile performance. Additionally, equity risk exists as prices of equities may be influenced by various factors, impacting their value regardless of company-specific performance. Complete information on the risks associated with the Fund can be found in the Fund's prospectus.